Histone deacetylase inhibitors: Discovery and development as anticancer agents

Expert Opinion on Investigational Drugs

Volumn 14, Issue 12, 2005, Pages 1497-1511

  Marks, Paul A ^a   Dokmanovic, Milos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; Histone acetyltransferases; Histone deacetylase; Histone deacetylase inhibitors; Suberoylanilide hydroxamic acid; Thioredoxin

Indexed keywords

4 N ACETYLDINALINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BL 1521; BORTEZOMIB; CARBOXYXINNAMIC ACID BISHYDROXAMIDE; DEPSIPEPTIDE; FLAVOPIRIDOL; FLUDARABINE; FR 901228; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NONHISTONE PROTEIN; OXAMFLATIN; PROTEIN; SULFONAMIDE; TRANSCRIPTION FACTOR; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GENE EXPRESSION REGULATION; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; NAUSEA; NONHUMAN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS;

EID: 28644440158     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.12.1497     Document Type: Review

References (104)

1. LEHRMANN H, PRITCHARD LL HAREL-BELLAN A: Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. (2002) 86:41-65.
2. LUGER K, MADER AW, RICHMOND RK, SARGENT DF, RICHMOND TJ: Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature (1997) 389:251-260.
3. MARKS P, RIFKIND RA, RICHON VM et al.: Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer (2001) 1:194-202.
4. FISCHLE W, WANG Y ALLIS CD: Binary switches and modification cassettes in histone biology and beyond. Nature (2003) 425:475-479.
5. SPOTSWOOD HT, TURNER BM: An increasingly complex code. J. Clin. Invest. (2002) 110:577-582.
6. ZHANG Y, REINBERG D: Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. (2001) 15:2343-2360.
7. FELSENFELD G, GROUDINE M: Controlling the double helix. Nature (2003) 421:448-453.
8. KHORASANIZADEH S: The nucleosome: from genomic organization to genomic regulation. Cell (2004) 116:259-272.
9. FISCHLE W, WANG Y ALLIS CD: Histone and chromatin cross-talk. Curr. Opin. Cell Biol. (2003) 15:172-183.
10. MARKS PA, RICHON VM, MILLER T KELLY WK: Histone deacetylase inhibitors. Adv. Cancer Res. (2004) 91:137-168.
11. DE RUIJTER AJ, VAN GENNIP AH, CARON HN, KEMP S, VAN KUILENBURG AB: Histone deacetylases: characterization of the classical HDAC family. Biochem. J. (2002) 370:737-749.
12. BLANDER G, GUARENTE L: The Sir2 family of protein deacetylases. Ann. Rev. Biochem (2004) 73:417-435.
13. MEI S, HO AD, MAHLKNECHT U: Role of histone deacetylase inhibitors in the treatment of cancer. Int. J. Oncol. (2004):1509-1519.
14. BHALLA KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. (2005) 23:3971-3993.
15. GREGORETTI IV, LEE YM, GOODSON HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. (2004) 338:17-31.
16. DRUMMOND DC, NOBLE CO, KIRPOTIN DB et al.: Clinical development of histone deacetylase inhibitors as anticancer agents. Ann. Rev. Pharmacol. Toxicol. (2005) 45:495-528.
17. MARKS P, KELLY W: Histone deacetylase inhibitors: novel targeted anti-cancer agents. In: DNA Methylation, Epigenetic and Metastasis. Esteller M, Springer, Netherlands (2005):269-305.
18. JOHNSTONE RW, LICHT JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell (2003) 4:13-18.
19. DI GENNARO E, BRUZZESE F, CARAGLIA M, ABRUZZESE A, BUDILLON A: Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids (2004) 26:435-441.
20. BUTLER LM, ZHOU X, XU W-S et al.: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci USA (2002) 99:11700-11705.
21. GUI CY, NGO L, XU WS, RICHON VM, MARKS PA: Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA (2004) 101:1241-1246.
22. SENGUPTA N, SETO E: Regulation of histone deacetylase activities. J. Cell. Biochem. (2004) 93:57-67.
23. WALTREGNY D, DE LEVAL L, GLENISSON W et al.: Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am. J. Pathol. (2004) 165:553-564.
24. YANG WM, TSAI SC, WEN YD, FEJER G, SETO E: Functional domains of histone deacetylase-3. J. Biol. Chem. (2002) 277:9447-9454.
25. ZHOU X, MARKS PA, RIFKIND RA, RICHON VM: Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. USA (2001) 98:10572-10577.
26. VERDIN E, DEQUIEDT F, KASLER HG: Class II histone deacetylases: versatile regulators. Trends Genet. (2003) 19:286-293.
27. GROZINGER CM, SCHREIBER SL: Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. USA (2000) 97:7835-7840.
28. LI X, SONG S, LIU Y, KO SH, KAO HY: Phosphorylation of the histone deacetylase 7 modulates its stability and association with 14-3-3 proteins. J. Biol. Chem. (2004) 279:34201-34208.
29. LAGGER G, O'CARROLL D, REMBOLD M et al.: Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. (2002) 21:2672-2681.
30. KOVACS JJ, MURPHY PJ, GAILLARD S et al.: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell (2005) 18:601-607.
31. KAWAGUCHI Y, KOVACS JJ, McLAURIN A et al.: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell (2003) 115:727-738.
32. MAHLKNECHT U, HOELZER D, BUCALA R, VERDIN E: Cloning and characterization of the murine histone deacetylase (HDAC3). Biochem. Biophys. Res. Commun. (1999) 263:482-490.
33. GROZINGER CM, HASSIG CA, SCHREIBER SL: Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. USA (1999) 96:4868-4873.
34. KAO HY, DOWNES M, ORDENTLICH P, EVANS RM: Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. (2000) 14:55-66.
35. DEQUIEDT F, KASLER H, FISCHLE W et al.: HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity (2003) 18:687-698.
36. KAO HY, LEE CH, KOMAROV A, HAN CC, EVANS RM: Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. (2002) 277:187-193.
37. GAO L, CUETO MA, ASSELBERGS F, ATADJA P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. (2002) 277:25748-25755.
38. VEGA RB, MATSUDA K, OH J et al.: Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell (2004) 119:555-566.
39. CHANG S, McKINSEY TA, ZHANG CL et al.: Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. (2004) 24:8467-8476.
40. ZHANG CL, McKINSEY TA, CHANG S et al.: Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell (2002) 110:479-488.
41. MEJAT A, RAMOND F, BASSEL-DUBY R et al.: Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat. Neurosci. (2005) 8:313-321.
42. TAKAMI Y, KIKUCHI H, NAKAYAMA T: Chicken histone deacetylase-2 controls the amount of the IgM H-chain at the steps of both transcription of its gene and alternative processing of its pre-mRNA in the DT40 cell line. J. Biol. Chem. (1999) 274:23977-23990.
43. GLASER KB, LI J, STAVER MJ et al.: Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. (2003) 310:529-536.
44. ZHU P, MARTIN E, MENGWASSER J et al.: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 5:455-463.
45. TAKAMI Y, NAKAYAMA T: N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J. Biol. Chem. (2000) 275:16191-16201.
46. TOU L, LIU Q, SHIVDASANI RA: Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases. Mol. Cell. Biol. (2004) 24:3132-3139.
47. LIU F, DOWLING M, YANG XJ, KAO GD: Caspase-mediated specific cleavage of human histone deacetylase 4. J. Biol. Chem. (2004) 279:34537-34546.
48. HUANG Y, TAN M, GOSINK M, WANG KK, SUN Y: Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res. (2002) 62:2913-2922.
49. ZHANG Y, LI N, CARON C et al.: HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. (2003) 22:1168-1179.
50. ROSATO RR, GRANT S: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs (2004) 13:21-38.
51. CHOI JH, KWON HJ, YOON BI et al.: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. (2001) 92:1300-1304.
52. HALKIDOU K, GAUGHAN L, COOK S et al.: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 59:177-189.
53. LINDEMANN RK, GABRIELLI B, JOHNSTONE RW: Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle (2004) 3:779-788.
54. SHEBZUKHOV YV, KOROLEVA EP, KHLGATIAN SV et al.: Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int. J. Cancer (2005) 117(5):800-806.
55. OSADA H, TATEMATSU Y, SAITO H et al.: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int. J. Cancer (2004) 112:26-32.
56. SCANLAN MJ, WELT S, GORDON CM et al.: Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. (2002) 62:4041-4047.
57. ZHANG Z, YAMASHITA H, TOYAMA T et al.: HDAC6 expression is correlated with better survival in breast cancer. Clin. Cancer Res. (2004) 10:6962-6968.
58. HE TC, CHAN TA, VOGELSTEIN B, KINZLER KW: PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 99:335-345.
59. YOSHIDA N, OMOTO Y, INOUE A et al.: Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci. (2004) 95:496-502.
60. MILLER TA, WITTER DJ, BELVEDERE S: Histone deacetylase inhibitors. J. Med. Chem. (2003) 46:5097-5116.
61. RICHON VM, EMILIANI S, VERDIN E et al.: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA (1998) 95:3003-3007.
62. JOSE B, ONIKI Y, KATO T et al.: Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg. Med. Chem. Lett. (2004) 14:5343-5346.
63. CURTIN M, GLASER K: Histone deacetylase inhibitors: the abbott experience. Curr. Med. Chem. (2003) 10:2373-5392.
64. YOSHIDA M, MATSUYAMA A, KOMATSU Y, NISHINO N: From discovery to the coming generation of histone deacetylase inhibitors. Curr. Med. Chem. (2003) 10:2351-2358.
65. GAREA-VILLAR A, ESTELLER M: histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer (2004) 112:171-178.
66. PARK JH, JUNG Y, KIM TY et al.: Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. (2004) 10:5271-5281.
67. HAGGARTY SJ, KOELLER KM, WONG JC, GROZINGER CM, SCHREIBER SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA (2003) 100:4389-4394.
68. FINNIN MS, DONIGIAN JR, COHEN A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401:188-193.
69. SOMOZA JR, SKENE RJ, KATZ BA et al.: Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 12:1325-1334.
70. GRAY SG, QIAN CN, FURGE K, GUO X, TEH BT: Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int. J. Oncol. (2004) 24:773-795.
71. PEART MJ, SMYTH GK, VAN LAAR RK et al.: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA (2005) 102:3697-3702.
72. MITSIADES CS, MITSIADES NS, McMULLAN CJ et al.: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA (2004) 101:540-545.
73. RASCLE A, JOHNSTON JA, AMATI B: Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol. Cell. Biol. (2003) 23:4162-4173.
74. VAN LINT C, EMILIANI S, VERDIN E: The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Exp. (1996) 5:245-254.
75. CHAMBERS AE, BANERJEE S, CHAPLIN T et al.: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer (2003) 39:1165-1175.
76. RICHON VM, SANDHOFF TW, RIFKIND RA, MARKS PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA (2000) 97:10014-10019.
77. WARRENER R, BEAMISH H, BURGESS A et al.: Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. (2003) 17:1550-1552.
78. ZHU P, HUBER E, KIEFER F, GOTTLICHER M: Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis. Cell Cycle (2004) 3:1240-1242.
79. BURGESS A, RUEFLI A, BEAMISH H et al.: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene (2004) 23:6693-6701.
80. UNGERSTEDT JS, SOWA Y, XU WS et al.: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA (2005) 102:673-678.
81. MARKS PA, JIANG X: Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle (2005) 4:e8-e11.
82. XU W-S, PEREZ G, NGO L, GUI C-Y, MARKS PA: Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res. (2005) 65(17):7832-7839.
83. SHAO Y, GAO Z, MARKS PA, JIANG X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA (2004) 101:18030-18035.
84. ROSATO RR, ALMENARA JA, DAI Y, GRANT S: Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. (2003) 2:1273-1284.
85. POWIS G, MUSTACICH D, COON A: The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. (2000) 29:312-322.
86. HOLMGREN A: Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid. Redox Signal (2000) 2:811-820.
87. RUNDLOF AK ARNER ES: Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signal (2004) 6:41-52.
88. ARNER ES, HOLMGREN A: Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. (2000) 267:6102-6109.
89. PIEKARZ R, BATES S: A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. (2004) 10:2289-2298.
90. GUO F, SIGUA C, TAO J et al.: Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. (2004) 64:2580-2589.
91. COFFEY DC, KUTKO MC, GLICK RD et al.: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. (2001) 61:3591-3594.
92. YOSHIDA C, MELO JV: Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. J. Hematol. (2004) 79:420-433.
93. PEI XY, DAI Y, GRANT S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. (2004) 10:3839-3852.
94. GEORGE P, BALI P, ANNAVARAPU S et al.: Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood (2005) 105:1768-1776.
95. FUINO L, BALI P, WITTMANN S et al.: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. (2003) 2:971-984.
96. KELLY WK, O'CONNOR OA, KRUG L et al.: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), in patients with advanced cancer. J. Clin. Oncol (2005) 23:3923-3931.
97. MIE LEE Y, KIM SH, KIM HS et al.: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem. Biophys. Res. Commun. (2003) 300:241-246.
98. BLANCHARD F, KINZIE E, WANG Y et al.: FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene (2002) 21:6264-6277.
99. PIEKARZ RL, ROBEY RW, ZHAN Z et al.: T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood (2004) 103:4636-4643.
100. KELLY W, MARKS P: Drug Insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clinical Practice Oncology (2005) 2:150-157.
101. DUVIC M, RAKHSHANDRA T, CHIAO J, CHIAO N: Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Blood (2003) 102(11):625 (Abstract).
102. KUENDGEN A, STRUPP C, AIVADO M et al.: Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood (2004) 104:1266-1269.
103. NERVI C, COCO FL, MINUCCI S et al.: Valproic acid plus retinoic acid induce myeloid differentiation in chemotherapy-resistant acute myeloid leukemia patients. ASH Annual Meeting Abstracts (2004) 104:1805.
104. DOKMANOVIC M, MARKS PA: Prospects: histone deacetylase inhibitors. J. Cell. Biochem. (2005) 96:293-304.